NIAGEN
LIVE

Serial Number

98788240

Owner

CHROMADEX, INC.

Attorney

Susan M. Natland

Filing Date

Oct 7, 2024

Add to watchlist:

No watchlists yet
View on USPTO

NIAGEN Trademark

Serial Number: 98788240

NIAGEN is a trademark filed by CHROMADEX, INC. on October 7, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

CHROMADEX, INC. (2 trademarks)

10900 Wilshire Blvd., Suite 600
Los Angeles, CA 90024

Entity Type: 03

Trademark Details

Filing Date

October 7, 2024

Registration Date

Not Registered

Goods & Services

Active chemical ingredients for use in the manufacturing of dietary supplements, nutritional supplements, pharmaceuticals, cosmetics, cosmetic preparations, pet products being nutritional supplements for animals, and personal care products; chemical reagents for non-medical purposes; chemicals for use in industry and science; chemicals for use in the biochemical and chemical industry; assays for research purposes; diagnostic preparations for scientific or research use; test kits comprised of chemical preparations and chemical reagents for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for scientific research purposes, other than for medical or veterinary use; test kits comprised of chemical agents and chemical preparations for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for scientific research purposes, other than for medical or veterinary use; specimen collection kits comprised primarily of chemically treated non-medical test strips and chemically treated non-medical test media in the form of cards and also including, laboratory swabs, plastic bags for transmitting specimens, printed mailing labels, and tubes for holding specimens for scientific research purposes, other than for medical or veterinary use; test kits comprised of chemical agents and chemically treated non-medical test media in the form of a card for testing for markers in bodily fluids, liquids, saliva and tissue for non-medical purposes; chemical preparations and articles, namely, chemical test paper, chemically treated non-medical test media in the form of strips and cards for the testing of nicotinamide adenine dinucleotide levels for purposes of assessing cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for scientific purposes, other than for medical or veterinary use

Pharmaceutical preparations, namely, nicotinamide riboside chloride for injection; injectable pharmaceutical preparations for use in hydration, vitamin, healthy aging, and wellness therapies; injectable pharmaceutical preparations for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, and muscle health; pharmaceutical preparations, namely, nicotinamide riboside chloride for use in intravenous therapy; medical diagnostic assays for testing of bodily fluids for analyzing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes; diagnostic kits comprised of medical diagnostic test media in the form of a card and sanitizing wipes for testing biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes; diagnostic kits comprising diagnostic agents and preparations for medical purposes; specimen collection kits for medical purposes comprised primarily of swabs for medical purposes and also including medical diagnostic test strips for blood analysis, plastic bags for transmitting medical specimens, printed mailing labels, and tubes for holding specimens; medical test kits comprised primarily of swabs for medical purposes, medical diagnostic media in the form of test strips and cards for testing blood for analysis of biomarkers and levels of nicotinamide adenine dinucleotide, vitamins, metabolites, and enzymes for medical purposes, and also including lancets, adhesive bandages, plastic bags for transmitting medical specimens, and printed mailing labels for testing for markers in bodily fluids, saliva and tissue; diagnostic agents, preparations and substances for medical purposes; medical and veterinary diagnostic preparations and articles, namely, swabs for medical use, medical diagnostic test media in the form of strips and cards for blood analysis in the testing nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; nutritional supplements for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, muscle health, and for treating vitamin, metabolite, enzyme, and nicotinamide adenine dinucleotide deficiencies, all for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; pharmaceutical preparations for increasing health, healthy aging, cellular health, cellular repair, energy, heart health, muscle health, and for treating vitamin, metabolite, enzyme, and nicotinamide adenine dinucleotide deficiencies, all for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations, all for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging for medical and veterinary use; prefilled syringes being syringes sold filled with pharmaceutical preparations, namely, vitamins, and nicotinamide adenine dinucleotide precursors; injectors sold filled with pharmaceutical preparations, namely, vitamins and nicotinamide adenine dinucleotide precursors; prefilled syringes sold filled with pharmaceutical preparations, namely, nicotinamide adenine dinucleotide precursors for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; injectors sold filled with pharmaceutical preparations, namely, nicotinamide adenine dinucleotide precursors for promoting nicotinamide adenine dinucleotide levels, cellular energy, brain health, muscle health and recovery, immune health, heart health, cellular energy and repair, stress management, and healthy aging; prefilled syringes sold filled with nicotinamide riboside chloride; injectors sold filled with nicotinamide riboside chloride; pharmaceutical preparations, namely, nicotinamide riboside chloride in the form of an injectable pharmaceutical

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 9, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 8, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 6, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 6, 2026 XELR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 5, 2026 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 5, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 5, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 5, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 5, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 5, 2026 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Dec 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Dec 8, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 28, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 28, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 28, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 11, 2025 GNRN
NON-FINAL ACTION E-MAILED
Aug 11, 2025 GNRT
NON-FINAL ACTION WRITTEN
Aug 11, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 16, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 16, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 16, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 16, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 16, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 10, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 9, 2025 NWOS
NEW APPLICATION ENTERED
Oct 7, 2024 NWAP